Neurocrine Biosciences, Inc. · NASDAQ:NBIX

Neurocrine Biosciences — Oppenheimer Conference 2009

31 slides from Neurocrine Biosciences's conference presentation, Nov 3, 2009

  1. Slide 1: Oppenheimer Conf 11-03-09

    Oppenheimer Conf 11-03-09 1

  2. Slide 2: Forward-looking statements and risks

    This presentation includes early and late stage clinical data and projections based thereon that involve a number of risks and uncertainties. These risks include the specific risk that the clinical development of the products discussed will not successfully proceed to later stage clinical trials or

  3. Slide 3: Pipeline

    Pipeline Products Indication Preclinical Phase 1 Phase 2 Phase 3 Elagolix Endometriosis Elagolix Benign Prostatic Hyperplasia CRF1 Antagonist Anxiety/Depression (561679) CRF1 Antagonist (586529) Anxiety/Depression CRF2 Agonist (Urocortin 2) Cardiovascular VMAT2 Inhibitor Movement Disorders (NBI-9885

  4. Slide 4: 2010 Milestones

    2010 Milestones • Elagolix 901 Study Results • Elagolix End of Phase II Meeting • Elagolix Special Protocol Assessment • Elagolix l li Initiate ii Phase h III with i h Partner • CRF Phase II Proof of Concept Results • VMAT2 D Dose EEscalation l ti St Study d • VMAT2 Investigational New Drug Applicat

  5. Slide 5: GnRH Program

    GnRH Program Orally Available, Nonpeptide Antagonists Oppenheimer Conf 11-03-09 5

  6. Slide 6: Clinical Trials As Of October 2009

    Clinical Trials As Of October 2009 Subjects On Phase Description Study Number Total Subjects Elagolix Ph 1 SD / MD, female NBI‐56418‐0301 55 45 Ph 1 Site absorption, male NBI‐56418‐0401 6 6 Ph 1 SD,, male NBI‐56418‐0402 8 8 Ph 1 Formulation, relative PK, male NBI‐56418‐0404 11 11 Ph 1 6‐wk, female N

  7. Slide 7: Early Phase IIa Studies

    Early Phase IIa Studies NBI‐56418‐0501 NBI 56418 0501 /0504 Treatment Results With Elagolix Oppenheimer Conf 11-03-09 7

  8. Slide 8: Key Efficacy Endpoints 3-Month

    Key Efficacy Endpoints 3‐Month 0501 and 0504 Studies: Week 12 Placebo Elagolix Study Study Study Study Study Study Endpoint Statistic 0501 0504 0501 0504 0501 0504 75 mg qd 50 mg bid 150 mg 100 mg qd bid (n=28) (n=20) (n=25) (n=21) (n=23) (n=24) CFB CPSSS Mean ‐3.7 ‐4.5 ‐3.8 ‐4.4 ‐5.2 ‐5.9 Baseline

  9. Slide 9: NBI-56418-0603

    NBI 56418 0603 NBI‐56418‐0603 Treatment and Post Treatment Results With Elagolix Oppenheimer Conf 11-03-09 9

  10. Slide 10: Clinically Meaningful and Statistically Significant Change from Baseline

    Clinically Meaningful and Statistically Significant Change from Baseline Secondary endpoints p<0.0001 LS Mean* Score Reduction at Month 6 Mean Score Elagolix Elagolix DMPA-SC Efficacy Assessment at Baseline 150 mg qd 75 mg bid 104 mg n=252 n=54 n=63 n=48 CPSSS Total 9.1 -5.5 -5.2 -5.3 Dysmenorrhea 2

  11. Slide 11: Dysmenorrhea

    Dysmenorrhea Mean Score by Study Week Week 24 Week 48 P<0.0001 P<0.0001 Oppenheimer Conf 11-03-09 11

  12. Slide 12: Responders: Dysmenorrhea

    Responders: Dysmenorrhea Improvement of ≥1 Point During Treatment 100 90 80 70 Responders 60 150 mg q.d. 50 75 mg b.i.d. Percent R DMPA‐SC 40 30 20 10 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Oppenheimer Conf 11-03-09 12

  13. Slide 13: Non-Menstrual Pelvic Pain

    Non‐Menstrual Pelvic Pain Mean Score by Study Week Week 24 Week 48 P<0.0001 P<0.0001 Oppenheimer Conf 11-03-09 13

  14. Slide 14: Responders: Non-Menstrual Pain

    Responders: Non‐Menstrual Pain Improvement of ≥1 Point During Treatment 100 90 80 70 Percent Responderss 60 150 mg q.d. 50 75 mg b.i.d. DMPA‐SC 40 30 20 10 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Oppenheimer Conf 11-03-09 14

  15. Slide 15: Improvement In EHP-5 Core Dimensions

    Improvement In EHP‐5 Core Dimensions Subject % Reporting Impact of Endometriosis Symptoms “Never” or “Rarely” Interfering with Life 90 80 70 60 50 40 30 20 10 0 Pain Control Well‐being Well being Social Self Image Support Baseline Month 6 Month 12 Data for subjects randomized to Elagolix 150 mg once

  16. Slide 16: Non-Menstrual Pain Score

    Non‐Menstrual Pain Score Monthly Recall Scores Comparable 3 • Non‐menstrual pain at Baseline consistent across trials using monthly recall component of B&B scale » Lupron vs. DMPA from 2 pivotall non‐inferiority f trial* l* Lupron » DMPA vs. Elagolix 150 mg qd DMPA from Petal Study** DMPA 603 1 • Al

  17. Slide 17: NBI-56418-0702 6-Month Treatment Results

    NBI‐56418‐0702 6‐Month Treatment Results Oppenheimer Conf 11-03-09 17

  18. Slide 18: Efficacy Endpoints: Elagolix vs. Placebo

    Efficacy Endpoints: Elagolix vs. Placebo Week 12 Results, ITT Population Placebo 150 mg LS Mean Change From Baseline to Week 12 n=52 n=51 Dysmenorrhea (mean daily pain, 0‐3) ‐0.25 ‐0.68** Dyspareunia (monthly mean, 0‐3) ‐0.29 ‐0.67* Non‐Menstrual Non Menstrual Pelvic Pain (mean daily pain, pain 00‐3

  19. Slide 19: Baseline Data Comparison – 0702 Study

    Baseline Data Comparison – 0702 Study NMPP Severity Shift: Monthly Recall vs. Daily Query Percentage of Subjects by Monthly Percentage of Daily NMPP Values by CPSSS NMPP Score at Baseline l Severity at Baseline l 1.8 mean score 0.8 mean score 2.0 median score 1.0 median score Oppenheimer Conf 11-03-

  20. Slide 20: Daily NMPP During 0702 Placebo Lead-In Period

    Daily NMPP During 0702 Placebo Lead‐In Period Two subjects with “moderate” NMPP on monthly recall Inter‐ and intra‐subject variability: day to day fluctuations demonstrated by daily scale data collection and focus groups confirm pain is episodic. Mean scores of <1 (e.g., 0.4 and 0.8) at baseline do

  21. Slide 21: Pain Dimension Scores from EHP-5

    Pain Dimension Scores from EHP‐5 Functional Impact of 6 Months of Treatment “Found it Difficult to Walk “Unable to Carry Out Duties at Work Pain” Because of Pain Due to Pain” 100 100 Baseline 90 90 Week 12 80 80 Week 24 70 70 ubjects 60 60 50 % Su 50 40 40 30 30 20 20 10 10 0 0 150 mg 250 mg 150 mg

  22. Slide 22: Patient Global Impression of Change

    Patient Global Impression of Change “Much Improved, Very Much Improved” (PGIC≤2) 90 80 70 ** * ** 60 * Percent of Subjects 50 Placebo 150 mgg q q.d. 40 ** 250 mg q.d. * 30 20 10 * P<0.05 ** P<0.01 0 Week 1 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Week 30 Oppenheimer Conf 11-03-09 22

  23. Slide 23: Monthly Scale Scores

    Monthly Scale Scores Sustained Effect at 6 Months Placebo to Placebo to Elagolix Elagolix Scale 150 mg qd 250 mg qd 150 mg qd 250 mg qd Mean Dysparuenia M D i Score S 1.1* 1 1* 0.9* 0 9* 1.0** 1 0** 1.1** 1 1** (0‐3, baseline mean=2) n=11 n=16 n=33 n=23 Mean Score EHP‐5: Core 25.0 12.5** 20.6*** 19.

  24. Slide 24: Pain Patterns Reported in Focus Groups

    Pain Patterns Reported in Focus Groups Focus groups confirm the findings of the 702 study, pain during non‐menstrual portion of cycle is i intermittent/less i /l severe than h menstruall pain, i andd rarely disabling Most Severe Most severe pain Some observe a spike in pain during perceived ovulatio

  25. Slide 25: FDA Type C Meeting - NMPP

    FDA Type C Meeting ‐ NMPP • Neurocrine shared elagolix clinical trial data (individual and group) » Intermittent pattern of reported daily non‐menstrual pain in 0702 study » Statistical “down scoring” from monthly CPSSS NMPP to the FDA‐ suggested daily NMPP • The FDA now requires a daily assessment

  26. Slide 26: Daisy Petal Study (901 Study)

    Daisy Petal Study (901 Study) Currently Enrolling Week -4 1 4 8 12 16 20 24 30 Wash- Randomized, Double- Blind, Screening g Open-Label p Phase Follow-up p out Placeco Controlled Tx 2-5 days 2-5 days after onset after onset of menses of menses Screening g Lap confirmed endometriosis, Placebo 6 months

  27. Slide 27: Baseline Eligibility

    Baseline Eligibility 901 Subjects to Conform with FDA Position • To assure a study population with moderate or severe endometriosis, subjects must meet inclusion criteria » Screening: Monthly‐recall CPSSS ≥6 ƒ reflects endometriosis of at least moderate severity pain, bleeding, g, analgesic g use,,

  28. Slide 28: Baseline Comparisons of Mean Scores

    Baseline Comparisons of Mean Scores All Studies Include Subjects with Moderate or Severe Disease Scales* 603 702 901 (randomized) (randomized) (preliminary**)) (preliminary Screening Total CPSSS monthlyy 9.1 8.6 9.4 Mean Dysmenorrhea Monthly 2.4 2.4 2.6 Daily ‐ 1.3 2.0 Mean Non‐Menstrual Pain Monthl

  29. Slide 29: 901 Baseline Characteristics

    901 Baseline Characteristics Preliminary Data From Subjects Eligible For Randomization Percentage of Daily NMP Values by Percentage of Daily NMPP Values by Severity at Baseline: 901 Severity at Baseline: 702 Oppenheimer Conf 11-03-09

  30. Slide 30: Summary

    Summary • Elagolix has good safety and tolerability profile in >800 subjects » Minimal risk of bone loss at 150 mg once daily • Efficacy confirmed across wide range of scales in 150 150‐250 250 mg dose range » Dysmenorrhea (monthly and daily) » Dyspareunia (monthly) » Non‐menstrual pain (monthly) »

  31. Slide 31: Financial Highlights

    Financial Highlights Year Ending Quarter Ending December 31, 2008 September 30, 2009 Revenues and $ 2.7 million $ 3.8 million other income Operating and other $ 91.3 million $ 46.9 million Expenses Net loss $ (88.6) million $ (43.1) million Cash and Investments $ 101.5 million $ 63.7 million Oppenhe

Neurocrine Biosciences — Oppenheimer Conference 2009 on 6ix